Back to top
more

Intercept Pharmaceuticals, Inc. (ICPT)

(Delayed Data from NSDQ)

$89.92 USD

89.92
705,568

+1.71 (1.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $89.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ICPT]

Reports for Purchase

Showing records 141 - 160 ( 867 total )

Industry: Medical - Biomedical and Genetics

Record: 141

10/01/2020

Industry Report

Pages: 20

Monthly Check-UpMonthly Check-Up

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 142

09/25/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 143

09/23/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 144

09/18/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 145

09/15/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 146

09/14/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 147

09/11/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 148

09/04/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 149

09/02/2020

Company Report

Pages: 7

Intercept Expects $18M Charge for Workforce Reduction From NASH Commercial Delay

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 150

08/31/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 151

08/28/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 152

08/28/2020

Company Report

Pages: 7

EASL: Biomarker Analysis Supports OCA?s Durable Fibrosis Effect; PBC OLE Data

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 153

08/24/2020

Company Report

Pages: 9

Q2 PBC Growth; FDA NASH Clarity in Q4; EASL Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 154

08/23/2020

Industry Report

Pages: 11

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 155

08/21/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 156

08/16/2020

Industry Report

Pages: 12

HEALTHCARE - The Week Ahead in Life SciencesThis report contains brief updates on the following: BMRN, VYGR, AQST, AXLA, ICPT, IMUX, VRNA, BPMC, MGNX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 157

08/14/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 158

08/13/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 159

08/11/2020

Company Report

Pages: 8

2Q20 Recap: All Eyes on Type A Meeting for NASH; PBC Sales Hits New High; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 160

08/07/2020

Daily Note

Pages: 4

Weekly Symphony Health Estimates for OCALIVA?

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party
// eof